{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Squamous+Cell+Head+and+Neck+Carcinoma&page=31",
    "query": {
      "condition": "Squamous Cell Head and Neck Carcinoma",
      "page": 31
    },
    "page_size": 10
  },
  "pagination": {
    "page": 31,
    "page_size": 10,
    "total_count": 1499,
    "total_pages": 150,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Squamous+Cell+Head+and+Neck+Carcinoma&page=32&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Squamous+Cell+Head+and+Neck+Carcinoma&page=30&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-16T20:10:35.397Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01115790",
      "title": "A Phase 1 Study in Participants With Advanced Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Cancer",
        "Squamous Cell Carcinoma",
        "Carcinoma, Squamous Cell of Head and Neck",
        "Lung Squamous Cell Carcinoma Stage IV",
        "Anal Squamous Cell Carcinoma",
        "Carcinoma, Non-Small-Cell Lung"
      ],
      "interventions": [
        {
          "name": "Prexasertib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 150,
      "start_date": "2010-02",
      "completion_date": "2016-01",
      "has_results": false,
      "last_update_posted_date": "2016-05-10",
      "last_synced_at": "2026-10-16T20:10:35.397Z",
      "location_count": 5,
      "location_summary": "Sarasota, Florida • Oklahoma City, Oklahoma • Nashville, Tennessee + 1 more",
      "locations": [
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01115790"
    },
    {
      "nct_id": "NCT00049140",
      "title": "EF5 Compared With Other Methods of Detecting Oxygen Levels in Tumor Cells of Patients With Head and Neck Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Cancer"
      ],
      "interventions": [
        {
          "name": "EF5",
          "type": "DRUG"
        },
        {
          "name": "bioluminescence",
          "type": "OTHER"
        },
        {
          "name": "flow cytometry",
          "type": "OTHER"
        },
        {
          "name": "immunohistochemistry staining method",
          "type": "OTHER"
        },
        {
          "name": "biopsy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "David M. Brizel, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2002-08",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2014-07-25",
      "last_synced_at": "2026-10-16T20:10:35.397Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00049140"
    },
    {
      "nct_id": "NCT00843635",
      "title": "Tadalafil in Treating Patients Undergoing Surgery for Cancer of the Oral Cavity or Oropharynx",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Head and Neck Cancer"
      ],
      "interventions": [
        {
          "name": "Tadalafil",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Donald T. Weed",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 35,
      "start_date": "2008-09",
      "completion_date": "2015-04",
      "has_results": true,
      "last_update_posted_date": "2015-10-19",
      "last_synced_at": "2026-10-16T20:10:35.397Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00843635"
    },
    {
      "nct_id": "NCT07768189",
      "title": "A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Oropharyngeal Carcinoma (OPC)"
      ],
      "interventions": [
        {
          "name": "CRB-701",
          "type": "DRUG"
        },
        {
          "name": "capcitabine",
          "type": "DRUG"
        },
        {
          "name": "Cetuximab (EGFR inhibitor)",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Corbus Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 260,
      "start_date": "2026-09-29",
      "completion_date": "2029-03",
      "has_results": false,
      "last_update_posted_date": "2026-10-08",
      "last_synced_at": "2026-10-16T20:10:35.397Z",
      "location_count": 38,
      "location_summary": "Huntsville, Alabama • Tucson, Arizona • Duarte, California + 32 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07768189"
    },
    {
      "nct_id": "NCT00258297",
      "title": "Gefitinib in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer That Can Be Removed By Surgery",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Esophageal Cancer"
      ],
      "interventions": [
        {
          "name": "gefitinib",
          "type": "DRUG"
        },
        {
          "name": "conventional surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "enzyme inhibitor therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "neoadjuvant therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "protein tyrosine kinase inhibitor therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "University of Rochester",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2004-04",
      "completion_date": "2006-11",
      "has_results": false,
      "last_update_posted_date": "2013-10-16",
      "last_synced_at": "2026-10-16T20:10:35.397Z",
      "location_count": 1,
      "location_summary": "Rochester, New York",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00258297"
    },
    {
      "nct_id": "NCT00004897",
      "title": "Combination Chemotherapy and Interferon Alfa Followed by Surgery and/or Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Esophageal Cancer"
      ],
      "interventions": [
        {
          "name": "recombinant interferon alfa",
          "type": "BIOLOGICAL"
        },
        {
          "name": "cisplatin",
          "type": "DRUG"
        },
        {
          "name": "fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "hydroxyurea",
          "type": "DRUG"
        },
        {
          "name": "leucovorin calcium",
          "type": "DRUG"
        },
        {
          "name": "conventional surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": null,
      "start_date": "1999-10",
      "completion_date": "2007-11",
      "has_results": false,
      "last_update_posted_date": "2012-06-12",
      "last_synced_at": "2026-10-16T20:10:35.397Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00004897"
    },
    {
      "nct_id": "NCT05784688",
      "title": "Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumor",
        "Biliary Tract Cancer",
        "Head and Neck Squamous Cell Carcinoma",
        "Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "TU2218 + KEYTRUDA® (Pembrolizumab)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "TiumBio Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 140,
      "start_date": "2023-03-10",
      "completion_date": "2028-12",
      "has_results": false,
      "last_update_posted_date": "2025-03-30",
      "last_synced_at": "2026-10-16T20:10:35.397Z",
      "location_count": 3,
      "location_summary": "San Antonio, Texas • Tyler, Texas • Spokane, Washington",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        },
        {
          "city": "Tyler",
          "state": "Texas"
        },
        {
          "city": "Spokane",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05784688"
    },
    {
      "nct_id": "NCT06525220",
      "title": "A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Head and Neck Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Petosemtamab",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merus B.V.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 699,
      "start_date": "2024-09-25",
      "completion_date": "2030-07",
      "has_results": false,
      "last_update_posted_date": "2026-09-25",
      "last_synced_at": "2026-10-16T20:10:35.397Z",
      "location_count": 36,
      "location_summary": "Mobile, Alabama • La Jolla, California • Los Angeles, California + 30 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Newark",
          "state": "Delaware"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06525220"
    },
    {
      "nct_id": "NCT02538627",
      "title": "Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Colorectal Cancer",
        "Non-small Cell Lung Cancer",
        "Squamous Cell Carcinoma of the Head and Neck"
      ],
      "interventions": [
        {
          "name": "MM-151",
          "type": "DRUG"
        },
        {
          "name": "MM-121",
          "type": "DRUG"
        },
        {
          "name": "MM-141",
          "type": "DRUG"
        },
        {
          "name": "trametinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merrimack Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2015-08",
      "completion_date": "2016-10-05",
      "has_results": false,
      "last_update_posted_date": "2017-09-05",
      "last_synced_at": "2026-10-16T20:10:35.397Z",
      "location_count": 5,
      "location_summary": "Aurora, Colorado • Sandy Springs, Georgia • Chicago, Illinois + 2 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Sandy Springs",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02538627"
    },
    {
      "nct_id": "NCT04074967",
      "title": "Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Renal Cell Carcinoma",
        "Melanoma",
        "Solid Tumor",
        "Non-small Cell Lung Cancer",
        "Head and Neck Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Phase Ib ARRY-614 + nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Phase Ib ARRY-614 + nivolumab+ipilimumab",
          "type": "DRUG"
        },
        {
          "name": "Phase II ARRY-614 + nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Phase II ARRY-614 + nivolumab+ipilimumab (melanoma)",
          "type": "DRUG"
        },
        {
          "name": "Phase II ARRY-614 + nivolumab+ipilimumab (RCC)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dan Zandberg",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 70,
      "start_date": "2020-06-11",
      "completion_date": "2025-12-31",
      "has_results": false,
      "last_update_posted_date": "2025-11-06",
      "last_synced_at": "2026-10-16T20:10:35.397Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04074967"
    }
  ]
}